- Home
- CTMX vs ODV Comparison
CTMX vs ODV Comparison
Compare CTMX & ODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ODV
- Stock Information
- Founded
- CTMX 2008
- ODV 2005
- Country
- CTMX United States
- ODV Canada
- Employees
- CTMX N/A
- ODV N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ODV Precious Metals
- Sector
- CTMX Health Care
- ODV Basic Materials
- Exchange
- CTMX Nasdaq
- ODV Nasdaq
- Market Cap
- CTMX 349.6M
- ODV 338.9M
- IPO Year
- CTMX 2015
- ODV N/A
- Fundamental
- Price
- CTMX $2.13
- ODV $2.91
- Analyst Decision
- CTMX Strong Buy
- ODV
- Analyst Count
- CTMX 3
- ODV 0
- Target Price
- CTMX $5.67
- ODV N/A
- AVG Volume (30 Days)
- CTMX 4.1M
- ODV 1.0M
- Earning Date
- CTMX 11-06-2025
- ODV 08-12-2025
- Dividend Yield
- CTMX N/A
- ODV N/A
- EPS Growth
- CTMX 263.20
- ODV N/A
- EPS
- CTMX 0.49
- ODV N/A
- Revenue
- CTMX $141,100,000.00
- ODV $5,147,156.00
- Revenue This Year
- CTMX N/A
- ODV $381.12
- Revenue Next Year
- CTMX N/A
- ODV $256.81
- P/E Ratio
- CTMX $4.66
- ODV N/A
- Revenue Growth
- CTMX 18.01
- ODV N/A
- 52 Week Low
- CTMX $0.40
- ODV $1.16
- 52 Week High
- CTMX $3.10
- ODV $3.03
- Technical
- Relative Strength Index (RSI)
- CTMX 49.61
- ODV 63.01
- Support Level
- CTMX $2.02
- ODV $2.73
- Resistance Level
- CTMX $2.17
- ODV $2.89
- Average True Range (ATR)
- CTMX 0.14
- ODV 0.16
- MACD
- CTMX 0.03
- ODV 0.02
- Stochastic Oscillator
- CTMX 55.42
- ODV 73.91
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.